These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Neoadjuvant Therapy for Locally Advanced Esophageal Cancer Should Be Targeted to Tumor Histology. Stiles BM; Kamel MK; Harrison SW; Rahouma M; Lee B; Nasar A; Port JL; Altorki NK Ann Thorac Surg; 2019 Jan; 107(1):187-193. PubMed ID: 30278165 [TBL] [Abstract][Full Text] [Related]
4. Splenic and PB immune recovery in neoadjuvant treated gastrointestinal cancer patients. Cole KE; Ly QP; Hollingsworth MA; Cox JL; Fisher KW; Padussis JC; Foster JM; Vargas LM; Talmadge JE Int Immunopharmacol; 2022 May; 106():108628. PubMed ID: 35203041 [TBL] [Abstract][Full Text] [Related]
5. Morbidity and Mortality of Patients Who Underwent Minimally Invasive Esophagectomy After Neoadjuvant Chemoradiotherapy vs Neoadjuvant Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma: A Randomized Clinical Trial. Wang H; Tang H; Fang Y; Tan L; Yin J; Shen Y; Zeng Z; Zhu J; Hou Y; Du M; Jiao J; Jiang H; Gong L; Li Z; Liu J; Xie D; Li W; Lian C; Zhao Q; Chen C; Zheng B; Liao Y; Li K; Li H; Wu H; Dai L; Chen KN JAMA Surg; 2021 May; 156(5):444-451. PubMed ID: 33729467 [TBL] [Abstract][Full Text] [Related]
6. Comparison of neoadjuvant immunotherapy plus chemotherapy versus chemotherapy alone for patients with locally advanced esophageal squamous cell carcinoma: A propensity score matching. Jing SW; Zhai C; Zhang W; He M; Liu QY; Yao JF; Wang R; Tian ZQ; Wang J; Liu JF Front Immunol; 2022; 13():970534. PubMed ID: 36275724 [TBL] [Abstract][Full Text] [Related]
7. Neoadjuvant chemoradiotherapy improves survival in locally advanced adenocarcinoma of esophagogastric junction compared with neoadjuvant chemotherapy: a propensity score matching analysis. Li J; Zhao Q; Ge X; Song Y; Tian Y; Wang S; Liu M; Qiao X BMC Surg; 2021 Mar; 21(1):137. PubMed ID: 33731072 [TBL] [Abstract][Full Text] [Related]
8. Tumor-immune landscape patterns before and after chemoradiation in resectable esophageal adenocarcinomas. Soeratram TT; Creemers A; Meijer SL; de Boer OJ; Vos W; Hooijer GK; van Berge Henegouwen MI; Hulshof MC; Bergman JJ; Lei M; Bijlsma MF; Ylstra B; van Grieken NC; van Laarhoven HW J Pathol; 2022 Mar; 256(3):282-296. PubMed ID: 34743329 [TBL] [Abstract][Full Text] [Related]
9. Long-term survival based on pathologic response to neoadjuvant therapy in esophageal cancer. Tiesi G; Park W; Gunder M; Rubio G; Berger M; Ardalan B; Livingstone A; Franceschi D J Surg Res; 2017 Aug; 216():65-72. PubMed ID: 28807215 [TBL] [Abstract][Full Text] [Related]
10. The Impact of Signet Ring Cell Differentiation on Outcome in Patients with Esophageal and Gastroesophageal Junction Adenocarcinoma. van Hootegem SJM; Smithers BM; Gotley DC; Brosda S; Thomson IG; Thomas JM; Gartside M; van Lanschot JJB; Lagarde SM; Wijnhoven BPL; Barbour AP Ann Surg Oncol; 2019 Aug; 26(8):2375-2384. PubMed ID: 30941657 [TBL] [Abstract][Full Text] [Related]
11. An International Cohort Study of Prognosis Associated With Pathologically Complete Response Following Neoadjuvant Chemotherapy Versus Chemoradiotherapy of Surgical Treated Esophageal Adenocarcinoma. Cools-Lartigue J; Markar S; Mueller C; Hofstetter W; Nilsson M; Ilonen I; Soderstrom H; Rasanen J; Gisbertz S; Hanna GB; Elliott J; Reynolds J; Kisiel A; Griffiths E; Van Berge Henegouwen M; Ferri L Ann Surg; 2022 Nov; 276(5):799-805. PubMed ID: 35861351 [TBL] [Abstract][Full Text] [Related]
12. Pre-treatment tumor-infiltrating T cells influence response to neoadjuvant chemoradiotherapy in esophageal adenocarcinoma. Goedegebuure RSA; Harrasser M; de Klerk LK; van Schooten TS; van Grieken NCT; Eken M; Grifhorst MS; Pocorni N; Jordanova ES; van Berge Henegouwen MI; Pouw RE; Verheul HMW; van der Vliet JJ; van Laarhoven HWM; Thijssen VLJL; Bass AJ; De Gruijl TD; Derks S Oncoimmunology; 2021; 10(1):1954807. PubMed ID: 34377591 [TBL] [Abstract][Full Text] [Related]
13. Perioperative outcomes of neoadjuvant chemotherapy plus camrelizumab compared with chemotherapy alone and chemoradiotherapy for locally advanced esophageal squamous cell cancer. Zhang B; Zhao H; Wu X; Gong L; Yang D; Li X; Chen X; Li J; Wang W; Wu J; Xiao Q Front Immunol; 2023; 14():1066527. PubMed ID: 36825006 [TBL] [Abstract][Full Text] [Related]
14. Effect of neoadjuvant chemotherapy on the immune microenvironment in non-small cell lung carcinomas as determined by multiplex immunofluorescence and image analysis approaches. Parra ER; Villalobos P; Behrens C; Jiang M; Pataer A; Swisher SG; William WN; Zhang J; Lee J; Cascone T; Heymach JV; Forget MA; Haymaker C; Bernatchez C; Kalhor N; Weissferdt A; Moran C; Zhang J; Vaporciyan A; Gibbons DL; Sepesi B; Wistuba II J Immunother Cancer; 2018 Jun; 6(1):48. PubMed ID: 29871672 [TBL] [Abstract][Full Text] [Related]
15. Tumor-infiltrating Treg, MDSC, and IDO expression associated with outcomes of neoadjuvant chemotherapy of breast cancer. Li F; Zhao Y; Wei L; Li S; Liu J Cancer Biol Ther; 2018 Aug; 19(8):695-705. PubMed ID: 29621426 [TBL] [Abstract][Full Text] [Related]
16. Esophageal adenocarcinoma stage III: Survival based on pathological response to neoadjuvant treatment. Schwameis K; Zehetner J; Hagen JA; Oh DS; Worrell SG; Rona K; Cheng N; Samaan J; Green KM; Lipham JC Surg Oncol; 2017 Dec; 26(4):522-526. PubMed ID: 29113673 [TBL] [Abstract][Full Text] [Related]
17. Neoadjuvant chemotherapy or chemoradiotherapy for adenocarcinoma of the esophagus. Visser E; Edholm D; Smithers BM; Thomson IG; Burmeister BH; Walpole ET; Gotley DC; Joubert WL; Atkinson V; Mai T; Thomas JM; Barbour AP J Surg Oncol; 2018 Jun; 117(8):1687-1696. PubMed ID: 29806960 [TBL] [Abstract][Full Text] [Related]
18. High CD8 Koemans WJ; van Dieren JM; van den Berg JG; Meijer GA; Snaebjornsson P; Chalabi M; Lecot F; Riedl R; Krijgsman O; Hofland I; Broeks A; Voncken FEM; Peppelenbosch MP; Sosef MN; van Sandick JW; Kodach LL Histopathology; 2021 Aug; 79(2):238-251. PubMed ID: 33660299 [TBL] [Abstract][Full Text] [Related]
19. Intratumoral budding and automated CD8-positive T-cell density in pretreatment biopsies can predict response to neoadjuvant therapy in rectal adenocarcinoma. Farchoukh L; Hartman DJ; Ma C; Celebrezze J; Medich D; Bahary N; Frank M; Pantanowitz L; Pai RK Mod Pathol; 2021 Jan; 34(1):171-183. PubMed ID: 32661298 [TBL] [Abstract][Full Text] [Related]
20. Longitudinal immune monitoring of patients with resectable esophageal adenocarcinoma treated with Neoadjuvant PD-L1 checkpoint inhibition. van den Ende T; Ezdoglian A; Baas LM; Bakker J; Lougheed SM; Harrasser M; Waasdorp C; van Berge Henegouwen MI; Hulshof MCCM; Haj Mohammad N; van Hillegersberg R; Mook S; van der Laken CJ; van Grieken NCT; Derks S; Bijlsma MF; van Laarhoven HWM; de Gruijl TD Oncoimmunology; 2023; 12(1):2233403. PubMed ID: 37470057 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]